Search results for "cancer biomarker"

showing 10 items of 14 documents

Colorectal Cancer Cell Line SW480 and SW620 Released Extravascular Vesicles: Focus on Hypoxia-induced Surface Proteome Changes

2018

Background/aim Extravascular vesicle (EV) proteome closely reflects the proteome of the cell of origin. Therefore, cancer cell-derived EV proteomic analysis could help in identifying cancer biomarkers. This study's goal was to investigate hypoxia-induced proteomic changes in EV released from hypoxic human isogenic non-metastatic colorectal cancer cells SW480 and metastatic colorectal cancer cells SW620. Materials and methods EV were characterized by western blot, transmission electron microscopy, proteomic analysis using liquid chromatography time-of-flight-mass spectrometry and quantified by an label-free intensity-based absolute quantitation (iBAQ) approach. Results A total of 16 proteins…

0301 basic medicineCancer ResearchProteomeFocus (geometry)Colorectal cancerAdenocarcinomaExtracellular Vesicles03 medical and health sciences0302 clinical medicineWestern blotTandem Mass SpectrometryCell Line TumorBiomarkers TumormedicineHumansmedicine.diagnostic_testChemistryVesicleCancerGeneral MedicineHypoxia (medical)medicine.diseaseMolecular biologyCell HypoxiaNeoplasm Proteins030104 developmental biologyOncology030220 oncology & carcinogenesisProteomeCancer biomarkersmedicine.symptomColorectal NeoplasmsChromatography LiquidAnticancer Research
researchProduct

Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer

2019

Metabolism reprogramming is considered a hallmark of cancer. The study of bladder cancer (BC) metabolism could be the key to developing new strategies for diagnosis and therapy. This work aimed to identify tissue and urinary metabolic signatures as biomarkers of BC and get further insight into BC tumor biology through the study of gene-metabolite networks and the integration of metabolomics and transcriptomics data. BC and control tissue samples (n = 44) from the same patients were analyzed by High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance and microarrays techniques. Besides, urinary profiling study (n = 35) was performed in the same patients to identify a metabolomic profi…

0301 basic medicineCancer ResearchTaurinecancer biomarkersBiologycancer metabolic reprogramminglcsh:RC254-282ArticleTranscriptome03 medical and health scienceschemistry.chemical_compoundtranscriptomics0302 clinical medicineMetabolomicsmedicinemetabolic pathwaysTumor metabolomeBladder cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmetabolomicsMetabolic pathway030104 developmental biologyOncologyBiochemistrychemistry030220 oncology & carcinogenesisbladder cancerCancer biomarkersDNA microarraytumor metabolome
researchProduct

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

2017

We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected with NFAT-luciferase was used to study if changes in PD-L1 expression in cancer cell lines were functionally relevant. Five KRAS mutant cell lines with high PD-L1 expression (H441, H2291, H23, H2030 and A549) were exposed to GI50 inhibitor concentrations of a MEK inhibitor (trametinib) and an AKT inhibitor (AZD5363) for 3 weeks. Only 3/5 (H23, H2030 and A549) and 2/5 cell lines (H441 and H23) showed functionally significant increases in PD-L1 expression when exposed to…

0301 basic medicineOncologyCell signalingLung NeoplasmsLuminescenceImmunofluorescenceMutantCancer Treatmentlcsh:MedicineSignal transductionERK signaling cascademedicine.disease_causeJurkat cellsB7-H1 AntigenLung and Intrathoracic TumorsMajor Histocompatibility ComplexWhite Blood Cells0302 clinical medicineAnimal CellsCarcinoma Non-Small-Cell LungMedicine and Health Scienceslcsh:ScienceTrametinibMultidisciplinarymedicine.diagnostic_testT CellsChemistryPhysicsElectromagnetic RadiationMEK inhibitorSignaling cascadesOncology030220 oncology & carcinogenesisPhysical SciencesKRASCellular TypesResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyImmune CellsImmunologyResearch and Analysis MethodsImmunofluorescenceFluorescence03 medical and health sciencesCell Line TumorInternal medicineMD MultidisciplinarymedicineHumansImmunoassaysBlood Cellslcsh:RCancers and NeoplasmsBiology and Life SciencesCell BiologyCoculture TechniquesNon-Small Cell Lung Cancerrespiratory tract diseasesGenes ras030104 developmental biologyCell cultureMutationImmunologic TechniquesCancer researchClinical ImmunologyCancer biomarkerslcsh:QClinical MedicinePLoS ONE
researchProduct

Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma

2020

Contains fulltext : 235640.pdf (Publisher’s version ) (Closed access) Genome-wide association studies (GWAS) of esophageal adenocarcinoma (EAC) and its precursor, Barrett's esophagus (BE), have uncovered significant genetic components of risk, but most heritability remains unexplained. Targeted assessment of genetic variation in biologically relevant pathways using novel analytical approaches may identify missed susceptibility signals. Central obesity, a key BE/EAC risk factor, is linked to systemic inflammation, altered hormonal signaling and insulin-like growth factor (IGF) axis dysfunction. Here, we assessed IGF-related genetic variation and risk of BE and EAC. Principal component analys…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyEsophageal NeoplasmsMedizinSingle-nucleotide polymorphismGenome-wide association studyBiologyAdenocarcinomaPolymorphism Single NucleotideReceptor IGF Type 103 medical and health sciencesBarrett Esophagus0302 clinical medicineRisk FactorsSomatomedinsInternal medicineGenetic variationmedicineBiomarkers TumorSNPHumansGenetic Predisposition to DiseaseRisk factorGerm-Line MutationCancer Biomarkers and Molecular EpidemiologyInsulin-like growth factor 1 receptorGenetic associationAgedGeneral MedicineMiddle Agedmedicine.diseaseRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biology030220 oncology & carcinogenesisBarrett's esophagusFemaleHuman medicineCarrier ProteinsGenome-Wide Association StudySignal TransductionCarcinogenesis
researchProduct

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.

2017

Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biom…

0301 basic medicineOncologymedicine.medical_specialtyBone diseasemedicine.medical_treatmentDiseaseReviewBiomarkers; Blood serum; Liquid biopsy; Osteosarcoma; Personalized medicine; Oncology03 medical and health sciences0302 clinical medicineBlood serumInternal medicineosteosarcomamedicineLiquid biopsyChemotherapyliquid biopsybusiness.industrybiomarkersBiomarkerpersonalized medicinemedicine.disease3. Good health030104 developmental biologyblood serumOncology030220 oncology & carcinogenesisOsteosarcomaCancer biomarkersPersonalized medicinebusinessOncotarget
researchProduct

Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: a case-control study.

2009

Objectives: Oral contraceptives (OCP) are highly effective, safe and widely used. Higher exposure to endogenous and exogenous estrogens is generally thought to increase the risk of breast cancer. Therefore, this study was conducted to determine if oral contraceptive use affected the expression of CA 15-3, CEA and C-erb B-2 in the saliva of healthy women. Study design: The participants consisted of 87 healthy women (43 controls and 44 using oral contraceptives) ranging in age from 20 to 54 years. The volunteers participated by giving one ? time stimulated whole saliva samples. Then the samples were analysed for CA 15-3, CEA and C-erb B-2 concentrations. Results: The student t-test was used t…

CA15-3Adultmedicine.medical_specialtySalivaReceptor ErbB-2PopulationPhysiologyYoung AdultBreast cancerMedicineEndocrine systemHumanseducationSalivaGeneral DentistryGynecologyeducation.field_of_studybusiness.industryMucin-1Case-control studyCancerMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCarcinoembryonic AntigenOtorhinolaryngologyCase-Control StudiesUNESCO::CIENCIAS MÉDICASSurgeryCancer biomarkersFemalebusinessContraceptives OralMedicina oral, patologia oral y cirugia bucal
researchProduct

Serum levels of angiogenetic cancer biomarkers in men undergoing prostate biopsy. Preliminary data

2012

Background: The reduction of the number of negative prostate biopsies in patients with elevated serum PSA represents a major challenge. Several angiogenetic biomarkers are involved in carcinogenesis and cancer progression. The aim of our preliminary study was to investigate if their serum levels might be related to prostate cancer detection. Patients and Methods: Angiopoietin 2, Follistatin, G-CSF, HGF, IL-8, Leptin, PDGF- BB, PECAM-1, VEGF, PTH were the selected biomarkers for our research. They were measured by BioPlex immunoassay. As a preliminary step, consecutive unselected patients undergoing prostate biopsy for palpable prostate nodule and/or elevated PSA levels were entered. A 12-co…

CANCER BIOMARKERS PROSTATE BIOPSYSettore MED/24 - Urologia
researchProduct

Heat shock proteins as danger signals for cancer detection

2011

First discovered in 1962, heat shock proteins (HSPs) are highly studied with about 35,500 publications on the subject to date. HSPs are highly conserved, function as molecular chaperones for a large panel of “client” proteins and have strong cytoprotective properties. Induced by many different stress signals, they promote cell survival in adverse conditions. Therefore, their roles have been investigated in several conditions and pathologies where HSPs accumulate, such as in cancer. Among the diverse mammalian HSPs, some members share several features that may qualify them as cancer biomarkers. This review focuses mainly on three inducible HSPs: HSP27, HPS70, and HSP90. Our survey of recent …

Cancer Researchendocrine systemdetectionchemical and pharmacologic phenomenaCancer detectionReview ArticleBioinformaticsdanger signallcsh:RC254-28203 medical and health sciencesstress0302 clinical medicineHsp27Heat shock proteinMedicine030304 developmental biologyCancer0303 health sciencesbiologyHeat shock proteinbusiness.industryCancerhemic and immune systemsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHsp903. Good healthBiomarker (cell)Oncology030220 oncology & carcinogenesisbiological sciencesbiology.proteinbiomarkerCancer biomarkersbusinessFunction (biology)Frontiers in Oncology
researchProduct

Recent advances on nanomaterial based electrochemical and optical aptasensors for detection of cancer biomarkers

2018

Abstract Cancer is a real menace to all societies globally since it is the leading cause of premature mortality in men and women. The incidence of malignancies is enhancing as a result of plenty factors. Physically and economically concerns that occur in cancers patients cannot be neglected. However, current diagnostic methods and cure duration do not fulfill patients requirements. Therefore, it is essential to detect and diagnose cancer biomarkers as soon as possible and overcome the current burdens. Novel aptasensors is emerging as one of the most promising strategies for early recognition of cancer. Aptamers an artificial DNA or RNA sequences, possess plenty of merits such as easy produc…

Diagnostic methodsWeb of sciencebusiness.industryAptamer010401 analytical chemistryEarly detectionCancer02 engineering and technologyComputational biology021001 nanoscience & nanotechnologymedicine.disease01 natural sciences0104 chemical sciencesAnalytical ChemistryBiomarker (cell)MedicineCancer biomarkers0210 nano-technologybusinessSpectroscopyTrAC Trends in Analytical Chemistry
researchProduct

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melti…

2016

Background Already since the 1990s, promoter CpG island methylation markers have been considered promising diagnostic, prognostic, and predictive cancer biomarkers. However, so far, only a limited number of DNA methylation markers have been introduced into clinical practice. One reason why the vast majority of methylation markers do not translate into clinical applications is lack of independent validation of methylation markers, often caused by differences in methylation analysis techniques. We recently described RET promoter CpG island methylation as a potential prognostic marker in stage II colorectal cancer (CRC) patients of two independent series. Methods In the current study, we analy…

Male0301 basic medicineMESH: Sequence Analysis DNABisulfite sequencingAnalytic sensitivityMS-HRMMESH : AgedMESH : Promoter Regions GeneticPolymerase Chain Reaction[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH: DNA MethylationMESH : FemaleMESH : Proto-Oncogene Proteins c-retPromoter Regions GeneticMESH: CpG IslandsMESH : Polymerase Chain ReactionGenetics (clinical)MESH: AgedDNA methylationMESH : PrognosisMethylationMESH : CpG IslandsPrognosispyrosequencing030220 oncology & carcinogenesisMESH: Survival AnalysisDNA methylationFemaleMESH : Colorectal NeoplasmsMESH : Sensitivity and SpecificityColorectal NeoplasmsMESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerBiologySensitivity and SpecificityMESH: Proto-Oncogene Proteins c-retHigh Resolution MeltMESH: Prognosis03 medical and health sciencesMESH: Promoter Regions GeneticGeneticsHumansMolecular BiologyAgedMESH: HumansResearchMSPProto-Oncogene Proteins c-retMESH : HumansMESH: Polymerase Chain ReactionSequence Analysis DNASurvival AnalysisMolecular biologyMESH: Sensitivity and SpecificityMESH: Male030104 developmental biologyPyrosequencingIllumina Methylation AssayCpG IslandsCancer biomarkersClinical sensitivityPrimer (molecular biology)MESH : Survival AnalysisRETMESH: FemaleMESH : DNA MethylationMESH: Colorectal NeoplasmsDevelopmental BiologyMESH : Sequence Analysis DNA
researchProduct